

For Immediate Release

CyGenics forms new US subsidiary
CytoVations to acquire and develop cell technology

20th June 2005 – CyGenics, Ltd. (ASX: CYN), a leading adult stem cell biotechnology and immunotherapy company, announced the formation of a new subsidiary, CytoVations, focussed on addressing the needs of the growing cell therapy market in the US.

CytoVations will assess intellectual property for the CyGenics group and assist in the subsequent development of products. CytoVations will also seek suitable candidates for acquisitions and business partnerships, as well as providing management and consultancy services to various biotech and pharmaceutical companies in North America. The company has begun operations in New Jersey, within easy reach of more than 20 of America's top biotech and pharma companies, as well as several major state and national research and regulatory bodies.

“CytoVations will complement the work of the other CyGenics companies, in particular Cytomatrix and Cell Sciences,” said Dr John Flickinger, President of CytoVations. (Cytomatrix, based in Boston, Massachusetts, is focussed advancing its state-of-the-art cellular screening technologies and services. Cell Sciences, which markets and distributes the group's cell culture products, is based in Singapore.) “It will also provide a platform for CyGenics to forge ahead with new products and services.”

Dr. Flickinger holds a Ph.D. from the Universite de Sherbrooke and has postdoctoral training in pathology at M.S. Hershey Medical College of the Pennsylvania State University. He has held faculty appointments at both these universities. He has also held research, product development and quality assurance positions with a number



of major companies, including T.J. Lipton and Quaker Oats, and served on numerous committees and panels, including with the World Health Organization and the International Roundtable of Microbiologists.

Mr Steven Fang, Chief Executive Officer of CyGenics added, “CytoVations adds an important piece to the current business model of CyGenics. The subsidiary will provide CyGenics with greater access to the US market, the aim being to identify and expand our current cell culture product portfolio.”

About CyGenics

CyGenics is a biotechnology and immunotherapy company focused on the development and commercialisation of adult stem cell-related products, services, applications and technologies. From its headquarters in Australia, CyGenics operates three divisions: Singapore-based CordLife (tissue banking services, in particular, cord blood banking) and Cell Sciences (consumable cell culture products), and Cytomatrix (cell therapeutics and technology development) based in the USA. CyGenics is listed on the Australian Stock Exchange, under the symbol CYN. For more information, please visit www.cygenics.com.

For more information, please contact:

| | |
|---|--|
| Ronald Hee Corporate Communications & Marketing Manager CyGenics Ph: +61 3 9642 5580 Email: ronald.hee@cygenics.com | Rebecca Piercy Buchan Consulting Ph: +61 3 9866 4722 Mob: 0422 916 422 Email: rebeccap@bcg.com.au |
|---|--|